Waldencast agrees to sell Obagi Medical to Bridgepoint for up to $460 million

Waldencast

Waldencast

WALD

0.00
  • Waldencast agreed to sell Obagi Medical to Bridgepoint for an enterprise value of up to USD 460 million.
  • Closing is expected in Q3 2026, subject to customary conditions including required regulatory approvals.
  • Proceeds are earmarked to repay about USD 178 million of senior secured term loan owed to Lumina Capital Management.
  • Founders Michel Brousset and Hind Sebti are set to move with selected executives to run Obagi Medical with Bridgepoint.
  • Waldencast plans to concentrate investment on Milk Makeup, led by president and co-founder Mazdack Rassi.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010659PRIMZONEFULLFEED9729595) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.